Neprilysin inhibitors preserve renal function in heart failure

Recently the superiority of the angiotensin receptor neprilysin (NEP) inhibitor (ARNi) LCZ696 over the angiotensin converting enzyme inhibitor, enalapril, has been demonstrated [1]. Therapy for heart failure may be limited by deterioration of renal function secondary to pharmacological agents used in the management of the condition. NEP inhibition may have direct or indirect beneficial renal effects that contribute to this superiority. (See Fig. 1.) (See Table 1.)

Source: International Journal of Cardiology - November 6, 2014 Category: Cardiology Authors: Fiona Bodey, Ingrid Hopper, Henry Krum Tags: Letter to the Editor Source Type: research